Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD - Johannesburg, South Africa
Video navigation menu
- LDLR dependent pharmacotherapy for HoFH 02:14
- LDLR independent therapies: Lomitapide 04:36
- LDLR independent therapies: ANGPTL3 inhibition 05:14
- Treatment algorithm for HoFH 07:28
This presentation by Prof. Raal is the second part of a series titled "HoFH: The need to treat - creating awareness, understanding and insights".
Prof. Frederick Raal, MD, PhD is head of the Division of Endocrinology & Metabolism and director of the Carohydrate and Lipid Metabolism Research Unit at the University of Witwatersrand, Johannesburg, South Africa.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Ultragenyx.